Onesource Specialty Pharma Limited
ONESOURCE · 544292 · Healthcare · Pharmaceuticals
- Market cap
- Rs 17,994 Cr
- P/E
- No data: the source has not published this figure.
- P/B
- 3.09x
- 52W high / low
- Rs 1,925 / Rs 1,057
Our computed roe (-0.83%) diverges from BSE's own published figure (5.21%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed operating_margin (3.77%) diverges from BSE's own published figure (18.73%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Onesource Specialty Pharma
Onesource Specialty Pharma Limited is listed on the NSE under the symbol ONESOURCE and on the BSE under scrip code 544292. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 500, NIFTY 500 and NIFTY Smallcap 250. The company listed on 24 Jan 2025 and has a face value of Rs 1.
The latest available end-of-day price is Rs 1,569.6 (−0.51% on the day), for a market capitalisation of Rs 17,994 Cr. Price-to-book is 3.09x. The 52-week range is Rs 1,057 to Rs 1,925. The latest price is 59% of the way from the 52-week low to the 52-week high.
Against the 16-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 0.2 times the peer median of Rs 95,511 Cr. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Onesource Specialty Pharma Limited reported revenue of Rs 1,422 Cr and net profit of Rs -73.8 Cr, with a net margin of -5.19% and earnings per share of Rs -6.44 (consolidated statements).
Year-on-year change: revenue −1.76%; net profit not meaningful (a loss in one of the periods); EPS not meaningful (a loss in one of the periods).
At the same date the balance sheet shows total assets of Rs 8,210 Cr, shareholders' equity of Rs 5,831 Cr, total debt of Rs 1,276 Cr, cash of Rs 35.7 Cr, a debt-to-equity ratio of 0.22 and operating cash flow of Rs 8.5 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 1,543 Cr, net income of Rs -48.6 Cr and a net margin of -3.15%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Onesource Specialty Pharma Limited's ownership is split: promoters 30.47%; foreign institutional investors (FIIs) 19.46%; domestic institutional investors (DIIs) 24.21%; retail and other shareholders 25.86%.
Compared with the filing for 30 Jun 2026: promoter holding −0.01 percentage points; FII holding +0.27 percentage points; DII holding +0.83 percentage points.
The same filing lists reported promoter pledge of 38.79% and 79,770 shareholders on record.
Recent filings and corporate actions
104 BSE corporate announcements were filed by Onesource Specialty Pharma Limited in the past twelve months; the most frequent category is "Company Update" (73). The most recent is "Intimation about publication of newspaper advertisement - Extract of unaudited Standalone and Consolidated financial results for the quarte…" (Company Update), filed on 28 Oct 2026.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Torrent Pharmaceuticals Limited | Rs 4,580 | Rs 1,55,015 Cr | Rs 15,654 Cr | Rs 2,156 Cr | 73.16x | 27.30% |
| Laurus Labs Limited | Rs 2,244 | Rs 1,21,232 Cr | Rs 7,323 Cr | Rs 1,091 Cr | — | 22.38% |
| Zydus Lifesciences Limited | Rs 1,184.4 | Rs 1,18,203 Cr | Rs 29,052 Cr | Rs 4,593 Cr | 26.40x | 17.68% |
| Dr. Reddy's Laboratories Limited | Rs 1,345 | Rs 1,12,308 Cr | Rs 34,353 Cr | Rs 2,760 Cr | 40.02x | 7.84% |
| Cipla Limited | Rs 1,358 | Rs 1,09,706 Cr | Rs 28,855 Cr | Rs 2,854 Cr | 37.86x | 8.83% |
| Mankind Pharma Limited | Rs 2,469.3 | Rs 1,01,982 Cr | Rs 15,705 Cr | Rs 2,264 Cr | 45.45x | 14.78% |
| Aurobindo Pharma Limited | Rs 1,659.9 | Rs 95,511 Cr | Rs 35,625 Cr | Rs 3,711 Cr | 25.94x | 10.53% |
| Lupin Limited | Rs 1,989.9 | Rs 90,988 Cr | Rs 30,442 Cr | Rs 5,551 Cr | 16.44x | 27.89% |
| Glenmark Pharmaceuticals Limited | Rs 2,339 | Rs 66,007 Cr | Rs 18,236 Cr | Rs 1,798 Cr | 36.71x | 15.46% |
| Alkem Laboratories Limited | Rs 5,079 | Rs 60,719 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 28.15x | 16.72% |
| Biocon Limited | Rs 351.9 | Rs 57,346 Cr | Rs 17,638 Cr | Rs 416 Cr | — | 1.78% |
| Abbott India Limited | Rs 26,145 | Rs 55,558 Cr | Rs 7,295 Cr | Rs 1,615 Cr | 34.41x | 35.85% |
| Gland Pharma Limited | Rs 3,074.5 | Rs 50,717 Cr | Rs 7,045 Cr | Rs 1,129 Cr | 44.88x | 11.57% |
| IPCA Laboratories Limited | Rs 1,926.2 | Rs 48,868 Cr | Rs 10,293 Cr | Rs 1,375 Cr | 37.31x | 17.45% |
| Ajanta Pharma Limited | Rs 3,459.7 | Rs 43,367 Cr | Rs 5,993 Cr | Rs 1,135 Cr | 38.09x | 27.19% |
| Onesource Specialty Pharma LimitedThis company | Rs 1,569.6 | Rs 17,994 Cr | Rs 1,557 Cr | Rs -48.6 Cr | — | -0.83% |
| Median | Rs 2,244 | Rs 95,511 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 37.58x | 17.45% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Onesource Specialty Pharma
Same official industry (Pharmaceuticals)
- Torrent Pharmaceuticals LimitedTORNTPHARM · Market cap Rs 1,55,015 Cr
- Laurus Labs LimitedLAURUSLABS · Market cap Rs 1,21,232 Cr
- Zydus Lifesciences LimitedZYDUSLIFE · Market cap Rs 1,18,203 Cr
- Dr. Reddy's Laboratories LimitedDRREDDY · Market cap Rs 1,12,308 Cr
- Cipla LimitedCIPLA · Market cap Rs 1,09,706 Cr
- Mankind Pharma LimitedMANKIND · Market cap Rs 1,01,982 Cr
- Aurobindo Pharma LimitedAUROPHARMA · Market cap Rs 95,511 Cr
- Lupin LimitedLUPIN · Market cap Rs 90,988 Cr
Other Healthcare companies of a similar market capitalisation
- Granules India LimitedGRANULES · Market cap Rs 20,750 Cr
- Cohance Lifesciences LimitedCOHANCE · Market cap Rs 18,416 Cr
- Caplin Point Laboratories LimitedCAPLIPOINT · Market cap Rs 18,058 Cr
- Pfizer LimitedPFIZER · Market cap Rs 17,201 Cr
- Eris Lifesciences LimitedERIS · Market cap Rs 16,139 Cr
- Syngene International LimitedSYNGENE · Market cap Rs 16,091 Cr
- Vijaya Diagnostic Centre LimitedVIJAYA · Market cap Rs 15,066 Cr
- Jubilant Pharmova LimitedJUBLPHARMA · Market cap Rs 14,947 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.